Credit Suisse Group Analysts Give Sanofi (EPA:SAN) a €105.00 Price Target

Credit Suisse Group set a €105.00 ($122.09) target price on Sanofi (EPA:SAN) in a research report released on Thursday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

Several other research firms have also weighed in on SAN. Morgan Stanley set a €105.00 ($122.09) target price on Sanofi and gave the company a buy rating in a report on Monday, January 6th. Barclays set a €80.00 ($93.02) target price on Sanofi and gave the company a sell rating in a report on Wednesday, January 1st. Deutsche Bank set a €92.00 ($106.98) target price on Sanofi and gave the company a buy rating in a report on Wednesday, December 11th. Jefferies Financial Group set a €110.00 ($127.91) target price on Sanofi and gave the company a buy rating in a report on Tuesday, December 17th. Finally, JPMorgan Chase & Co. set a €103.00 ($119.77) target price on Sanofi and gave the company a buy rating in a report on Monday, January 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. Sanofi presently has an average rating of Buy and a consensus price target of €96.42 ($112.12).

SAN opened at €92.19 ($107.20) on Thursday. Sanofi has a 1 year low of €63.09 ($73.36) and a 1 year high of €92.97 ($108.10). The stock has a fifty day moving average price of €88.63 and a 200 day moving average price of €81.67.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: Range Trading

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit